SCHEDULE: 5AM Ventures Significantly Reduces Stake in VOR Biopharma, Drops Below 5% Ownership

5AM Ventures and its affiliated entities have substantially decreased their holdings in VOR Biopharma Inc., divesting nearly 2 million shares and ceasing to be a beneficial owner of more than five percent of the company's common stock.

Summary

• 5AM Ventures VI, L.P. and 5AM Opportunities I, L.P., along with their general partners and managing members Andrew J. Schwab and Kush Parmar, filed an Amendment No. 2 to their Schedule 13D.
• On July 8, 2025, 5AM Ventures VI, L.P. sold 1,400,444 shares of VOR Biopharma common stock in open market transactions.
• On the same date, 5AM Opportunities I, L.P. sold an additional 538,416 shares of VOR Biopharma common stock in open market transactions.
• The sales were executed at prices ranging from $2.40 to $3.00 per share, with a weighted average sales price of $2.4568 per share.
• Following these transactions, the Reporting Persons collectively ceased to be beneficial owners of more than five percent of VOR Biopharma's common stock as of July 8, 2025.
• As of the filing, Andrew J. Schwab and Kush Parmar beneficially own an aggregate of 4,422,863 shares, representing 3.5% of the outstanding common stock.
• The percentage of ownership is based on 124,959,520 shares of common stock outstanding as of May 8, 2025, as reported in VOR Biopharma's Quarterly Report on Form 10-Q filed on May 14, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative because a major institutional investor has significantly reduced its stake, dropping below the 5% ownership threshold. This often signals a lack of confidence or a strategic exit, which can be perceived negatively by the market.

Negatives

• A significant reduction in ownership by a major institutional investor like 5AM Ventures could be perceived negatively by the market, potentially signaling a loss of confidence or a strategic portfolio reallocation.
• The sale of 1,938,860 shares represents a substantial divestment from their previous position.
• The Reporting Persons ceasing to be a greater than 5% beneficial owner removes them from a category of significant influence and mandatory disclosure requirements for future minor changes.

Risks

• Investor confidence risk: The divestment by a major investor might lead to decreased investor confidence in VOR Biopharma.
• Share price volatility: Such a large sale could put downward pressure on the company's stock price due to increased supply and negative sentiment.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding VOR Biopharma's future operations or financial performance, focusing solely on the change in beneficial ownership.

Management Comments

• The document does not contain any direct quotes or paraphrased statements from VOR Biopharma's management. It includes signatures from the managing members of the reporting entities, Andrew J. Schwab and Kush Parmar, certifying the accuracy of the filing.

Industry Context

This filing reflects a portfolio adjustment by a venture capital firm, 5AM Ventures, in a biotechnology company. Such divestments by early-stage investors are common as companies mature or as investment theses evolve, but can also signal a shift in investor sentiment within the biotech sector, particularly concerning companies like VOR Biopharma that are likely in clinical development stages.

Comparison to Industry Standards

• This Schedule 13D filing reports a change in beneficial ownership by an institutional investor, 5AM Ventures, in VOR Biopharma Inc. This type of disclosure is standard practice for investors whose ownership crosses certain thresholds.
• There are no specific operational or financial results within this document to compare against industry benchmarks or specific comparable companies/projects.
• The action itself, a venture capital firm reducing its stake, is a common occurrence in the lifecycle of biotech investments, often seen as a fund reaching its investment horizon or rebalancing its portfolio.
• The specific reasons for the divestment are not disclosed, making direct comparisons to other firms' investment strategies or specific project outcomes speculative.

Stakeholder Impact

• Shareholders: Existing shareholders may experience downward pressure on share price due to the large sale and potential loss of confidence following a major investor's divestment.
• Potential Investors: May view the reduction in stake by 5AM Ventures as a cautionary signal, potentially impacting future investment decisions.

Next Steps

• The document does not explicitly state any future actions or milestones for VOR Biopharma or the Reporting Persons beyond the filing itself.

Key Dates

Recommendation

Keywords

VOR Biopharma, 5AM Ventures, Schedule 13D, Beneficial Ownership, Stock Sale, Institutional Investor, Common Stock, SEC Filing, Equity Stake, Divestment